Sparks commentary - SynAct Pharma

Healthcare

Sparks - SynAct Pharma

More on this equity
SynAct Pharma (STO: SYNACT) confirms recruitment on-track in RA trial
Published by Arron Aatkar, PhD

SynAct Pharma has announced that its Phase IIb ADVANCE trial, evaluating lead asset resomelagon in patients with newly diagnosed rheumatoid arthritis (RA), is on-track to complete patient recruitment by end-2025, consistent with prior guided timelines, with 190 out of 240 participants now randomised. ADVANCE has been designed as a 12-week, randomised, placebo-controlled study. It is specifically targeting RA patients with high disease activity who are eligible for methotrexate treatment (the current standard of care). Top-line results are anticipated in Q126, and as this is the lead programme, it represents an important upcoming inflection point for SynAct.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.